How should I taper off Tofranil (imipramine)?

Slow hyperbolic taper recommended due to anticholinergic rebound. Compounded liquid useful for fine cuts at the low end. Reduce by smaller proportional steps as the dose gets lower. Cholinergic rebound (sweating, abdominal cramps, malaise) is common and often misread as relapse.

How long does Tofranil withdrawal last?

Tofranil withdrawal typically begins 1-3 days after dose reduction, peaks around 5-10 days, and resolves within 2-6 weeks for most symptoms. Sleep disturbance and emotional reactivity can persist 1-3 months

Forums/Drug Profiles/

Tofranil Tapering Guide

imipramine

TCAFDA 1959

Go to Community Forum

Boxed Warning

Suicidality risk in children, adolescents, and young adults under 25 during initial antidepressant treatment.

Overview

Imipramine is the prototype tricyclic antidepressant, FDA-approved for major depression and pediatric enuresis (bedwetting). Largely displaced by SSRIs but still used for treatment-resistant depression, panic disorder, and chronic pain.

Common Doses

10mg, 25mg, 50mg tablets; 75mg, 100mg, 125mg, 150mg capsules

Formulations

Tablets: 10mg, 25mg, 50mg; Capsules (pamoate): 75mg, 100mg, 125mg, 150mg

Pregnancy

Category C

Mechanism of Action

Inhibits reuptake of both serotonin and norepinephrine at the presynaptic terminal. Also blocks histamine H1, muscarinic, and alpha-1 adrenergic receptors — these "off-target" actions explain most of the side-effect profile.

Taper Notes

Slow hyperbolic taper recommended due to anticholinergic rebound. Compounded liquid useful for fine cuts at the low end.

Hyperbolic Tapering Guidance

Reduce by smaller proportional steps as the dose gets lower. Cholinergic rebound (sweating, abdominal cramps, malaise) is common and often misread as relapse.

Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.

Withdrawal Timeline

⏱Onset

1-3 days after dose reduction

📈Peak Severity

5-10 days

📉Resolution

2-6 weeks for most symptoms

⚠️Protracted Risk

Sleep disturbance and emotional reactivity can persist 1-3 months

Common Withdrawal Symptoms

flu-like symptomsGI upsetinsomniavivid dreamsakathisiacholinergic rebound (sweating, salivation, cramps)anxiety

Interactions & Safety

Drug Interactions

MAOIs — contraindicated (serotonin syndrome, hypertensive crisis)
CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion) — markedly increase imipramine levels
QT-prolonging agents — additive arrhythmia risk

Contraindications

Recent (within 14 days) MAOI use
Acute recovery phase after myocardial infarction
Narrow-angle glaucoma (relative)

Toxicity

Highly toxic in overdose — narrow therapeutic index. Cardiac arrhythmias, seizures, anticholinergic toxicity, coma. Even 1-2 weeks of supply can be lethal.

Pharmacokinetics

ADME Profile

Absorption

Well absorbed orally; extensive first-pass metabolism.

Metabolism

Hepatic via CYP1A2, CYP2C19, CYP2D6, CYP3A4 to active desipramine.

Elimination

Renal (80%) and fecal (20%) as metabolites.

Protein Binding

~90%

Need a clinician who understands tapering?

Browse our map of deprescribing-informed providers worldwide.

Find a Deprescriber

Other Drug Profiles

Lexapro

escitalopram — SSRI

Zoloft

sertraline — SSRI

Paxil

paroxetine — SSRI

Prozac

fluoxetine — SSRI

Sources & References

Tofranil (imipramine) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.

Encyclopedic & chemical databases

Neutral, high-authority entity references.

Regulatory sources

Official prescribing information and safety notices.

FDA prescribing information — Tofranil (imipramine)

Peer-reviewed research

Primary literature cited in this taper guide.

Horowitz MA, Taylor D 2019 — Tapering of SSRI treatment to mitigate withdrawal symptoms (hyperbolic taper) (The Lancet Psychiatry)
Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Framer A 2021 — The patient voice: an exploration of the experience of withdrawal from antidepressants (Therapeutic Advances in Psychopharmacology)

Clinical guidelines

Evidence-based deprescribing and prescribing standards.

Deprescribing-specific resources

Clinician-facing references on tapering protocols.

Deprescribing.org — Evidence-based deprescribing algorithms from the Bruyère Research Institute
Royal College of Psychiatrists — Stopping antidepressants — UK clinical guidance on safely discontinuing antidepressants

Patient-advocacy & lived-experience

Long-running communities documenting withdrawal experience.

Surviving Antidepressants — tapering forum — Long-running community archive of antidepressant taper experiences
Inner Compass Initiative — Withdrawal Project — Peer-led resources for psychiatric drug withdrawal
Mad in America — antidepressant withdrawal archive — Journalism and personal narratives on SSRI/SNRI discontinuation
RxISK — adverse drug reaction reporting — Independent database of patient-reported adverse effects

TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.